Our proposed therapeutic strategy bears a striking resemblance to the FDA approved anti-sclerostin antibodies used to treat osteoporosis.20 Sclerostin is a circulating protein that inhibits Wnt binding to Lrp5/6.21 Anti-sclerostin antibodies bind and neutralize sclerostin allowing Wnt binding to Lrp5/6 and sequestration of the β-catenin destruction complex. This evidence concerns the gene LRP5 and osteoporosis.